Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichi Ando

Showing results (21-30 of 241) with videos related to

Pageof 25
Sort By:
The Lancet. Oncology|December 19, 2015
Survival of patients with metastatic breast cancer with or without locoregional therapyKazunori Honda, Bishal Gyawali, Yuichi Ando
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Obvious Pitfall in the Estimation of Renal DysfunctionTomoya Shimokata, Yoshinari Yasuda, Yuichi Ando
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-LetterOsamu Maeda, Tomoya Shimokata, Yuichi Ando
Japanese Journal of Clinical Oncology|December 13, 2025
Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a reviewKazuyuki Mizuno, Osamu Maeda, Yuichi Ando
Japanese Journal of Clinical Oncology|January 6, 2024
Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitorsYao Liang, Osamu Maeda, Yuichi Ando
International Journal of Environmental Research and Public Health|December 8, 2023
Long- and Short-Term Trends in Outpatient Attendance by Speciality in Japan: A Joinpoint Regression Analysis in the Context of the COVID-19 PandemicAsuka Takeda, Yuichi Ando, Jun Tomio
Investigational New Drugs|November 4, 2005
Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecanMaki Ando, Yoshinori Hasegawa, Yuichi Ando
The New England Journal of Medicine|January 15, 2015
FOLFOXIRI and bevacizumab for metastatic colorectal cancerAyumu Matsuoka, Osamu Maeda, Yuichi Ando
Expert Review of Molecular Diagnostics|July 11, 2006
Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular AssayYoshinori Hasegawa, Yuichi Ando, Kaoru Shimokata
The Lancet. Oncology|December 19, 2015
TRIBE study: are all three cytotoxic drugs crucial?Ayumu Matsuoka, Osamu Maeda, Yuichi Ando
Pageof 25

Showing results (21-30 of 241) with videos related to

Sort By:
Pageof 25
The Lancet. Oncology|December 19, 2015
Survival of patients with metastatic breast cancer with or without locoregional therapyKazunori Honda, Bishal Gyawali, Yuichi Ando
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Obvious Pitfall in the Estimation of Renal DysfunctionTomoya Shimokata, Yoshinari Yasuda, Yuichi Ando
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-LetterOsamu Maeda, Tomoya Shimokata, Yuichi Ando
Japanese Journal of Clinical Oncology|December 13, 2025
Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a reviewKazuyuki Mizuno, Osamu Maeda, Yuichi Ando
Japanese Journal of Clinical Oncology|January 6, 2024
Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitorsYao Liang, Osamu Maeda, Yuichi Ando
International Journal of Environmental Research and Public Health|December 8, 2023
Long- and Short-Term Trends in Outpatient Attendance by Speciality in Japan: A Joinpoint Regression Analysis in the Context of the COVID-19 PandemicAsuka Takeda, Yuichi Ando, Jun Tomio
Investigational New Drugs|November 4, 2005
Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecanMaki Ando, Yoshinori Hasegawa, Yuichi Ando
The New England Journal of Medicine|January 15, 2015
FOLFOXIRI and bevacizumab for metastatic colorectal cancerAyumu Matsuoka, Osamu Maeda, Yuichi Ando
Expert Review of Molecular Diagnostics|July 11, 2006
Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular AssayYoshinori Hasegawa, Yuichi Ando, Kaoru Shimokata
The Lancet. Oncology|December 19, 2015
TRIBE study: are all three cytotoxic drugs crucial?Ayumu Matsuoka, Osamu Maeda, Yuichi Ando
Pageof 25